ASPI ASP Isotopes Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ASPI Stock | Fundamental Analysis & Investment Insights
NASDAQ
Basic Materials
Chemicals
Current Price
Live
$5.34
Analyst Target
$12.0
+124.7%
Upside
52W High
$14.49
52W Low
$3.65
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 28, 2026
Market cap
$668.09M
P/E
N/A
ROE
-152.6%
Profit margin
N/A
Debt/Equity
1.18
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ASPI's deterministic health scores signal severe financial distress: the Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score (with a Debt/Equity of 1.18 and negative ROE/ROA) raises significant bankruptcy risk. Despite a remarkable 349.5% YoY revenue growth, the company reports a 0.00% profit margin, -306.10% operating margin, and negative ROE of -152.56%, reflecting unsustainable profitability. Insider selling totaling $6.26M in six months, with no buys, underscores deteriorating confidence among management. The stock trades at a steep Price/Sales of 79.69 and Price/Book of 6.73, far exceeding peer averages, suggesting extreme overvaluation relative to fundamentals.
Key Strengths
Exceptional 349.5% year-over-year revenue growth indicates strong top-line momentum
High current and quick ratios (6.14 and 4.70) suggest strong short-term liquidity
Recent quarter showed positive Q/Q EPS growth (+85.4%), indicating potential earnings recovery
Significant 5-year stock appreciation (+100%) reflects strong market enthusiasm
Analyst target price of $12.00 implies a potential upside of 124% from current levels
Key Risks
Piotroski F-Score of 1/9 signals severe financial distress and operational failure
Negative operating margin (-306.10%) and ROE (-152.56%) indicate deep unprofitability
Insider selling of $6.26M in six months with no purchases reflects strong bearish sentiment
Price/Sales of 79.69 and Price/Book of 6.73 suggest extreme overvaluation
No dividend, no earnings, and no free cash flow make the stock fundamentally unattractive
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
10
40
15
10
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 1/9, Negative profitability metrics, Extreme valuation multiples, Massive insider selling, No analyst consensus
Confidence
85%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
- High revenue growth potential
Watchpoints
- Price/Sales of 79.69 is extremely high
- No Graham Number or intrinsic value available
- No earnings to support valuation
- Price/Book of 6.73 is elevated
- No cash flow or dividend to justify premium
Future
40/100
Ref Growth rates
Positives
- 349.5% YoY revenue growth
- Positive Q/Q EPS growth (+85.4%)
Watchpoints
- Forward P/E of -12.14 indicates continued losses
- No earnings guidance or sustainable growth path
- Negative ROIC and ROA suggest inefficient capital use
- No free cash flow data
- High debt/equity (1.18) limits future investment
Past
15/100
Ref Historical trends
Positives
- 5-year stock return of +100%
- 6-month price recovery from 52-week low
Watchpoints
- Consistent earnings misses (0/4 in last 4 quarters)
- Average earnings surprise of -302.12%
- Declining EPS YoY (-25.0%) despite revenue growth
- Negative ROE and ROA across all periods
- Persistent operating losses
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- High current and quick ratios (6.14, 4.70)
Watchpoints
- Piotroski F-Score of 1/9 (extreme weakness)
- Negative ROE (-152.56%) and ROA (-17.15%)
- Debt/Equity of 1.18 (above peer average of 0.61)
- No Altman Z-Score available (risk of distress)
- Negative operating margin (-306.10%)
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout
- Payout ratio of 0.00%
- No history of dividend payments
- Company is unprofitable and cash-constrained
- No indication of future dividend intent
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$5.34
Analyst Target
$12.0
Upside/Downside
+124.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ASPI and closest competitors.
Updated 2026-02-27
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ASPI
ASP Isotopes Inc.
Primary
|
+100.0% | +196.7% | +15.1% | -42.5% | -32.8% | +2.7% |
|
ASTL
Algoma Steel Group Inc.
Peer
|
-48.5% | -34.3% | -46.5% | -27.1% | +8.9% | +3.2% |
|
ASIX
AdvanSix Inc.
Peer
|
-19.6% | -57.0% | -44.5% | -20.6% | -0.2% | +0.4% |
|
ALTO
Alto Ingredients, Inc.
Peer
|
-18.0% | +142.7% | +253.0% | +294.9% | +68.2% | +6.2% |
|
AREC
American Resources Corporation
Peer
|
-32.2% | +122.1% | +571.7% | +53.2% | +7.6% | -1.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-12.14
PEG Ratio
N/A
P/B Ratio
6.73
P/S Ratio
79.69
EV/Revenue
73.25
EV/EBITDA
-14.79
Market Cap
$668.09M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-306.1%
Gross Margin
23.0%
ROE
-152.56%
ROA
-17.15%
Growth
Revenue and earnings growth rates
Revenue Growth
+349.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.18
Moderate
Current Ratio
6.14
Strong
Quick Ratio
4.7
Excellent
Cash/Share
$1.03
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-30
$N/A
2025-11-19
$-0.15
-50.0% surprise
2025-08-14
$-1.03
-836.4% surprise
2025-05-20
$-0.12
-20.0% surprise
Basic Materials Sector Comparison
Comparing ASPI against 41 companies in the Basic Materials sector
(1 bullish, 21 neutral, 19 bearish)
Return on Equity (ROE)
-152.56%
This Stock
vs
0.39%
Sector Avg
-38756.2%
(Below Avg)
Debt to Equity
1.18
This Stock
vs
0.61
Sector Avg
+94.2%
(Higher)
Revenue Growth
349.5%
This Stock
vs
14.81%
Sector Avg
+2260.3%
(Fast Growth)
Current Ratio
6.14
This Stock
vs
2.28
Sector Avg
+169.7%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ASPI
ASP Isotopes Inc.
|
BEARISH | $668.09M | - | -152.6% | -% | $5.34 | |
|
ASTL
Algoma Steel Group Inc.
|
BEARISH | $476.4M | - | -% | -34.8% | $4.54 | |
|
ASIX
AdvanSix Inc.
|
BEARISH | $458.57M | 8.89 | 6.6% | 3.5% | $17.07 | |
|
ALTO
Alto Ingredients, Inc.
|
NEUTRAL | $360.42M | 29.12 | 5.7% | 1.5% | $4.66 | |
|
AREC
American Resources Corporation
|
BEARISH | $320.6M | - | -% | -% | $3.11 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-18 | KIESSLING HEATHER | Chief Financial Officer | Sale | 80,000 | $463,840 |
| 2025-12-18 | WIDER TODD | Director | Stock Award | 36,548 | - |
| 2025-12-18 | RYAN ROBERT JOHN ANDREW | Director | Stock Award | 36,548 | - |
| 2025-12-18 | GORLEY MICHAEL | Director | Stock Award | 36,548 | - |
| 2025-12-18 | HUNTER RALPH L. JR | Director | Stock Award | 36,548 | - |
| 2025-12-08 | AINSCOW ROBERT | Chief Executive Officer | Sale | 8,438 | $52,341 |
| 2025-12-01 | MANN PAUL ELLIOT | Officer and Director | Sale | 162,153 | $932,866 |
| 2025-11-25 | MANN PAUL ELLIOT | Officer and Director | Sale | 162,500 | $1,132,988 |
| 2025-11-25 | AINSCOW ROBERT | Chief Executive Officer | Sale | 25,000 | $144,225 |
| 2025-11-17 | AINSCOW ROBERT | Chief Executive Officer | Sale | 67,500 | $506,722 |
| 2025-11-12 | WIDER TODD | Director | Stock Award | 25,469 | - |
| 2025-10-14 | AINSCOW ROBERT | Chief Executive Officer | Sale | 22,500 | $305,978 |
| 2025-09-30 | GORLEY MICHAEL | Director | Sale | 64,000 | $624,237 |
| 2025-09-15 | WIDER TODD | Director | Sale | 74,108 | $648,823 |
| 2025-09-12 | WIDER TODD | Director | Option Exercise | 96,000 | $192,000 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
2 analysts
Cantor Fitzgerald
2025-12-04
Overweight
Canaccord Genuity
2025-11-24
Buy
Buy
Canaccord Genuity
2025-09-17
Buy
Buy
Past News Coverage
Recent headlines mentioning ASPI from our newsroom.
Newest → oldest
No matching news yet.